Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)

European Journal of Haematology

Volumn 94, Issue 6, 2015, Pages 504-510

  Jung, Sung Hoon ^a   Lee, Je Jung ^a   Kim, Won Seog ^b   Lee, Won Sik ^c   Do, Young Rok ^d   Oh, Sung Yong ^e   Kim, Min Kyoung ^f   Mun, Yeung Chul ^g   Shin, Ho Jin ^h   Kwak, Jae Yong ⁱ   Kang, Hye Jin ^j   Won, Jong Ho ^k   Kwon, Jung Hye ^l   Park, Eunkyung ^m   Suh, Cheolwon ⁿ   Yang, Deok Hwan ^a  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Dong A Medical Center   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g Ewha Womans University   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

ⁱ Chonbuk National University Medical School   (South Korea)

^j Korea Institute of Radiation and Medical Science   (South Korea)

^k Soonchunhyang University   (South Korea)

^l Hallym University College of Medicine   (South Korea)

^m Chung Ang University College of Medicine   (South Korea)

ⁿ Asan Medical Center   (South Korea)

more..

Author keywords

Diffuse large B cell lymphoma; Elderly; Rituximab consolidation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPARATIVE STUDY; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; LARGE CELL LYMPHOMA; LUNG EMBOLISM; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VERY ELDERLY; AGE; CLINICAL TRIAL; DRUG ADMINISTRATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM STAGING; PREDNISONE; RITUXIMAB; TREATMENT OUTCOME; VINCRISTINE;

EID: 84929070416     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12459     Document Type: Article

References (26)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-76.
2. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol 2004;31:128-36.
3. Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw 2012;10:1487-98.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
5. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.
6. Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 2012;157:159-70.
7. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988;6:1838-44.
8. Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881-93.
9. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14:277-81.
10. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7.
11. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 460-8.
12. Shin HJ, Chung JS, Song MK, Kim SK, Choe S, Cho GJ. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 2012;69:1165-72.
13. Aoki K, Takahashi T, Tabata S, Kurata M, Matsushita A, Nagai K, Ishikawa T. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2013;54:2441-7.
14. Hainsworth JD, Flinn IW, Spigel DR, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk 2010; 10: 44-50.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
16. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on L. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
17. Maartense E, Kluin-Nelemans HC, le Cessie S, Kluin PM, Snijder S, Noordijk EM. Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. Cancer 2000;89:2667-76.
18. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103-10.
19. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
20. Musolino A, Boggiani D, Panebianco M, Vasini G, Salvagni S, Franciosi V, Ardizzoni A. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 2011;117:964-73.
21. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525-33.
22. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
23. Rothe A, Schulz H, Elter T, Engert A, Reiser M. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:875-6.
24. Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004; 15: 821-30.
25. Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 2014;55:526-32.
26. Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 2012;53:43-9.